Key Insights

Highlights

Success Rate

56% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.8%

4 terminated out of 41 trials

Success Rate

55.6%

-31.0% vs benchmark

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results56% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (4)
Early P 1 (3)
P 1 (25)
P 2 (3)
P 3 (1)
P 4 (2)

Trial Status

Recruiting21
Not Yet Recruiting10
Completed5
Terminated4
Active Not Recruiting1

Trial Success Rate

55.6%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT07476781Not ApplicableRecruitingPrimary

Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study

NCT07712835Completed

ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis

NCT07708103Early Phase 1Not Yet RecruitingPrimary

Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid Tumors

NCT07704515Phase 1Not Yet RecruitingPrimary

GKL-006Allo Injection in Patients With Advanced Solid Tumors

NCT07704866Phase 1Not Yet Recruiting

A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors

NCT07704658Phase 4Recruiting

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

NCT06896162Not ApplicableRecruitingPrimary

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT07174453Phase 3RecruitingPrimary

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

NCT07664397Phase 1Not Yet Recruiting

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

NCT07407582Phase 1RecruitingPrimary

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

NCT06136884Phase 1RecruitingPrimary

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

NCT07486713Phase 4Recruiting

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

NCT07207707Phase 1RecruitingPrimary

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

NCT07167381Not ApplicableRecruiting

xDRIVE for Florida-based Cancer Patients

NCT04668833Phase 2TerminatedPrimary

ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter

NCT05085548Phase 1Completed

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

NCT06720987Phase 1Recruiting

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT07303387Phase 2RecruitingPrimary

Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

NCT06960395Phase 1RecruitingPrimary

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07476534Not Yet RecruitingPrimary

Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression

Scroll to load more

Research Network

Activity Timeline